BioTech IP Review

This milestone was not a bench research article per se, but it was published and highlighted in Nature as a historic biotechnology advance in the editorial and commentary sections of the journal: the approval of the first CRISPR‑Cas9–based gene‑editing therapy (exagamglogene autotemcel, marketed as Casgevy) by the U.S. Food and Drug Administration for the treatment of sickle cell disease and transfusion‑dependent β‑thalassemia — a major step for gene editing reaching clinical impact.

---

What It Covers

Background:

• Sickle cell disease (SCD) and β‑thalassemia are genetic blood disorders caused by mutations in the HBB gene, which encodes the β‑globin subunit of hemoglobin. These conditions cause lifelong anemia, pain crises, organ damage, and can be life‑threatening.

What happened:

• In December 2023, the FDA approved exagamglogene autotemcel (Casgevy), a CRISPR‑Cas9–based gene‑editing therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals.
• The therapy involves ex vivo editing of a patient’s hematopoietic stem and progenitor cells to disrupt a regulatory gene (BCL11A) that represses fetal hemoglobin production, thereby allowing higher levels of fetal hemoglobin that can compensate for faulty adult hemoglobin.
• Patients treated showed substantial therapeutic benefit, with many free of severe pain crises for extended periods after treatment.

Why this matters:

• First CRISPR‑based therapy approved: This marked the first regulatory approval worldwide of a CRISPR gene‑editing therapy used in patients, turning decades of research into a clinically viable genetic cure for inherited disease.
• Clinical translation of gene editing: The success represents a pivotal transition from biodiscovery to practical treatment — a major biotechnology milestone in precision medicine and genome editing.
• Broad impact: Beyond these two hemoglobinopathies, the approval opened the door for future CRISPR therapies targeting other genetic diseases, potentially expanding curative treatments for conditions that were previously incurable.

---

Summary

The Nature-reported milestone of Casgevy’s approval was one of the most biotechnologically transformative events of the year: it marked the first approved CRISPR‑Cas9 gene‑editing therapy, validating targeted genome engineering as a therapeutic platform capable of delivering lasting clinical benefit in human genetic disease.